PFE PFIZER INC Insider Trading

Director BLAYLOCK RONALD E purchases 19,457 shares of PFE at $25.65, raising holdings 235.8% to 27,707 shares.

Director Ronald E. Blaylock purchased 19,457 shares at $25.65 on 2025-02-13, increasing his holdings by 235.8% from 8,250 to 27,707 shares and deploying approximately $499.1K in capital. The transaction occurred when PFE was trading -18.7% below its 52-week high and -2.6% below its 30-day average, though the stock has risen 2.9% over the past 90 days. With annual revenue declining -41.7% year-over-year and a P/E of 34.04, the company faces significant growth headwinds that warrant scrutiny alongside the director's substantive increase in personal stake.

Director Scott Gottlieb buys 1,000 PFE shares at $28.24; stock down 7.0% in 90 days, 1 of 3 prior buys at ticker showed positive 90d return

Gottlieb purchased 1,000 shares at $28.24, increasing his holdings to 10,000 shares (+11.1% vs pre-transaction holdings). Pfizer's stock has declined 7.0% over 90 days and is currently down 9.8% from its 52-week high of $31.39. His cross-ticker track record shows mixed results: 3 prior buys averaged +3.0% over 30 days but -4.0% over 90 days, with only a 33.33% win rate. At Pfizer specifically, his prior three purchases had inconsistent outcomes: one delivered +8.4% in 30 days and +6.3% in 90 days, while the other two posted negative 90-day returns of -9.2% and -8.9%, with only 1 of 3 prior PFE buys showing positive 90-day returns. The purchase occurs against a backdrop of significant fundamental headwinds—annual revenue contracted 41.7% year-over-year and net income stands at only $41.0M on quarterly revenue of $13.3B—leaving the timing and conviction signal of this transaction ambiguous.